Journal Article
. 2014 May;15(7).
doi: 10.1016/S1470-2045(14)70160-3.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gunter von Minckwitz 1 Andreas Schneeweiss 2 Sibylle Loibl 3 Christoph Salat 4 Carsten Denkert 5 Mahdi Rezai 6 Jens U Blohmer 7 Christian Jackisch 8 Stefan Paepke 9 Bernd Gerber 10 Dirk M Zahm 11 Sherko Kümmel 12 Holger Eidtmann 13 Peter Klare 14 Jens Huober 15 Serban Costa 16 Hans Tesch 17 Claus Hanusch 18 Jörn Hilfrich 19 Fariba Khandan 20 Peter A Fasching 21 Bruno V Sinn 5 Knut Engels 22 Keyur Mehta 23 Valentina Nekljudova 23 Michael Untch 24 
  • PMID: 24794243
  •     225 citations


Background: Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

Methods: Patients with previously untreated, non-metastatic, stage II-III, triple-negative breast cancer and HER2-positive breast cancer were enrolled. Patients were treated for 18 weeks with paclitaxel (80 mg/m(2) once a week) and non-pegylated liposomal doxorubicin (20 mg/m(2) once a week). Patients with triple-negative breast cancer received simultaneous bevacizumab (15 mg/kg intravenously every 3 weeks). Patients with HER2-positive disease received simultaneous trastuzumab (8 mg/kg initial dose with subsequent doses of 6 mg/kg intravenously every 3 weeks) and lapatinib (750 mg daily). Patients were randomly assigned in a 1:1 ratio with dynamic allocation and minimisation, stratified by biological subtype and Ki-67 level to receive, at the same time as the backbone regimens, either carboplatin (AUC 1·5 [2·0 for the first 329 patients] once a week) or no carboplatin. The primary endpoint the proportion of patients who achieved a pathological complete response (defined as ypT0 ypN0), analysed for all patients who started treatment; a p value of less than 0·2 was deemed significant for the primary endpoint. This trial is registered with, number NCT01426880.

Findings: 296 patients were randomly assigned to receive carboplatin and 299 to no additional carboplatin, of whom 295 and 293 started treatment, respectively. In this final analysis, 129 patients (43·7%, 95% CI 38·1-49·4) in the carboplatin group achieved a pathological complete response, compared with 108 patients (36·9%, 31·3-42·4) without carboplatin (odds ratio 1·33, 95% CI 0·96-1·85; p=0·107). Of the patients with triple-negative breast cancer, 84 (53·2%, 54·4-60·9) of 158 patients achieved a pathological complete response with carboplatin, compared with 58 (36·9%, 29·4-44·5) of 157 without (p=0·005). Of the patients with HER2-positive tumours, 45 (32·8%, 25·0-40·7) of 137 patients achieved a pathological complete response with carboplatin compared with 50 (36·8%, 28·7-44·9) of 136 without (p=0·581; test for interaction p=0·015). Haematological and non-haematological toxic effects that were significantly more common in the carboplatin group than in the no-carboplatin group included grade 3 or 4 neutropenia (192 [65%] vs 79 [27%]), grade 3 or 4 anaemia (45 [15%] vs one [<1%]), grade 3 or 4 thrombocytopenia (42 [14%] vs one [<1%]), and grade 3 or 4 diarrhoea (51 [17%] vs 32 [11%]); carboplatin was more often associated with dose discontinuations (141 [48%] with carboplatin and 114 [39%] without carboplatin; p=0·031). The frequency of grade 3 or 4 haematological events decreased from 82% (n=135) to 70% (n=92) and grade 3 or 4 non-haematological events from 78% (n=128) to 59% (n=77) in the carboplatin arm when the dose of carboplatin was reduced from AUC 2·0 to 1·5.

Interpretation: The addition of neoadjuvant carboplatin to a regimen of a taxane, an anthracycline, and targeted therapy significantly increases the proportion of patients achieving a pathological complete response. This regimen seems to increase responses in patients with triple-negative breast cancer, but not in those with HER2-positive breast cancer.

Funding: GlaxoSmithKline, Roche, and Teva.

Breast cancer: TNBC: can we treat the untargetable?
Lisa Hutchinson.
Nat Rev Clin Oncol, 2014 May 21; 11(7). PMID: 24840078
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
Aleix Prat, Cristina Cruz, +3 authors, Judith Balmaña.
Breast Cancer Res Treat, 2014 Jul 23; 147(1). PMID: 25048467    Free PMC article.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, +14 authors, Eric P Winer.
J Clin Oncol, 2014 Aug 06; 33(1). PMID: 25092775    Free PMC article.
Highly Cited.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
A Prat, A Lluch, +35 authors, E Alba.
Br J Cancer, 2014 Aug 08; 111(8). PMID: 25101563    Free PMC article.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
F Cardoso, A Costa, +40 authors, E Winer.
Ann Oncol, 2014 Sep 23; 25(10). PMID: 25234545    Free PMC article.
Highly Cited.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Assessing the role of platinum agents in aggressive breast cancers.
William M Sikov.
Curr Oncol Rep, 2015 Feb 11; 17(2). PMID: 25665554
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition.
Aaron Goldman, Biswanath Majumder, +5 authors, Shiladitya Sengupta.
Nat Commun, 2015 Feb 12; 6. PMID: 25669750    Free PMC article.
Highly Cited.
Landscape of neoadjuvant therapy for breast cancer.
Tufia C Haddad, Matthew P Goetz.
Ann Surg Oncol, 2015 Mar 03; 22(5). PMID: 25727557    Free PMC article.
Breast cancer under age 40: a different approach.
D Ribnikar, J M Ribeiro, +6 authors, F Cardoso.
Curr Treat Options Oncol, 2015 Mar 23; 16(4). PMID: 25796377
Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
N Maass, F Schütz, +7 authors, M P Lux.
Geburtshilfe Frauenheilkd, 2015 Mar 24; 75(2). PMID: 25797960    Free PMC article.
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Melinda L Telli, Kristin C Jensen, +18 authors, James M Ford.
J Clin Oncol, 2015 Apr 08; 33(17). PMID: 25847929    Free PMC article.
Highly Cited.
Therapies for triple negative breast cancer.
Eleni Andreopoulou, Sarah J Schweber, Joseph A Sparano, Hayley M McDaid.
Expert Opin Pharmacother, 2015 Apr 18; 16(7). PMID: 25881743    Free PMC article.
Tumor homologous recombination deficiency assays: another step closer to clinical application?
Shane R Stecklein, Priyanka Sharma.
Breast Cancer Res, 2014 Jan 01; 16(4). PMID: 25928813    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
Erika Vacchelli, Jonathan Pol, +9 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 May 08; 4(1). PMID: 25949870    Free PMC article.
Familial breast cancer - targeted therapy in secondary and tertiary prevention.
Karin Kast, Kerstin Rhiem.
Breast Care (Basel), 2015 May 12; 10(1). PMID: 25960722    Free PMC article.
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Fanny Le Du, Bedrich L Eckhardt, +5 authors, Naoto T Ueno.
Oncotarget, 2015 May 15; 6(15). PMID: 25973541    Free PMC article.
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
Vito Amoroso, Daniele Generali, +30 authors, Alberto Bottini.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063896    Free PMC article.
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Liang Huang, Sheng Chen, +13 authors, Zhiming Shao.
Oncotarget, 2015 Jun 19; 6(21). PMID: 26084292    Free PMC article.
Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis.
Muyou Tian, Yahua Zhong, +3 authors, Zhengkai Liao.
Mol Clin Oncol, 2015 Jul 03; 3(3). PMID: 26137293    Free PMC article.
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
M Untch, N Harbeck, +22 authors, S Loibl.
Geburtshilfe Frauenheilkd, 2015 Jul 15; 75(6). PMID: 26166836    Free PMC article.
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
A Schneeweiss, E Ruckhäberle, J Huober.
Geburtshilfe Frauenheilkd, 2015 Jul 15; 75(6). PMID: 26166838    Free PMC article.
Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.
Kathrin Halfter, Nina Ditsch, +9 authors, Behalf of the SpheroNEO Study Group.
BMC Cancer, 2015 Jul 15; 15. PMID: 26169261    Free PMC article.
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Mehra Golshan, Constance T Cirrincione, +8 authors, Alliance for Clinical Trials in Oncology.
Ann Surg, 2015 Jul 30; 262(3). PMID: 26222764    Free PMC article.
PARP inhibitors in the management of breast cancer: current data and future prospects.
Luca Livraghi, Judy E Garber.
BMC Med, 2015 Aug 14; 13. PMID: 26268938    Free PMC article.
Highly Cited. Review.
The role of taxanes in triple-negative breast cancer: literature review.
Giorgio Mustacchi, Michelino De Laurentiis.
Drug Des Devel Ther, 2015 Aug 15; 9. PMID: 26273192    Free PMC article.
Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.
Risa Takeda, Ayano Naka, +4 authors, Shingo Kamoshida.
Breast Cancer (Auckl), 2015 Aug 27; 9. PMID: 26309405    Free PMC article.
CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
Lisa A Carey.
Clin Cancer Res, 2015 Sep 17; 21(18). PMID: 26374072    Free PMC article.
Triple negative breast cancer: looking for the missing link between biology and treatments.
Giuseppe Palma, Giuseppe Frasci, +7 authors, Massimiliano D'Aiuto.
Oncotarget, 2015 Sep 21; 6(29). PMID: 26387133    Free PMC article.
Highly Cited. Review.
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
Qiao Li, Qing Li, +7 authors, Binghe Xu.
Cancer Biol Ther, 2015 Oct 16; 16(12). PMID: 26466918    Free PMC article.
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Meriem Boukerroucha, Claire Josse, +8 authors, Vincent Bours.
BMC Cancer, 2015 Oct 23; 15. PMID: 26490435    Free PMC article.
SEOM clinical guidelines in early-stage breast cancer 2015.
J A Garcia-Saenz, B Bermejo, +7 authors, E Ciruelos.
Clin Transl Oncol, 2015 Oct 27; 17(12). PMID: 26497356    Free PMC article.
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Patrizia Vici, Anna Di Benedetto, +19 authors, Marcello Maugeri-Saccà.
Oncotarget, 2015 Nov 07; 6(40). PMID: 26544894    Free PMC article.
Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.
Joerg Heil, Sherko Kümmel, +10 authors, Gunter von Minckwitz.
Br J Cancer, 2015 Nov 12; 113(11). PMID: 26554654    Free PMC article.
Targeted Therapies in Triple-Negative Breast Cancer.
Frederik Marmé, Andreas Schneeweiss.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557820    Free PMC article.
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.
Christian Jackisch, Nadia Harbeck, +22 authors, Michael Untch.
Breast Care (Basel), 2015 Nov 12; 10(3). PMID: 26557827    Free PMC article.
Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.
Agnieszka Kolacinska, Barbara Cebula-Obrzut, +7 authors, Piotr Smolewski.
Oncol Lett, 2015 Dec 02; 10(2). PMID: 26622629    Free PMC article.
Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Junjun Liu, Xiaosong Chen, +2 authors, Kunwei Shen.
Tumour Biol, 2016 Jan 27; 37(7). PMID: 26810188
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
Gaurav Goyal, Tiffany Fan, Peter Todd Silberstein.
Fam Cancer, 2016 Feb 14; 15(3). PMID: 26873719    Free PMC article.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, +22 authors, Andrea L Richardson.
Clin Cancer Res, 2016 Mar 10; 22(15). PMID: 26957554    Free PMC article.
Highly Cited.
Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.
Fiona Haxho, Ronald J Neufeld, Myron R Szewczuk.
Oncotarget, 2016 Oct 27; 7(26). PMID: 27029067    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
Diana H Liang, Dong Soon Choi, +3 authors, Jenny C Chang.
Cancer Lett, 2016 Apr 10; 376(2). PMID: 27060208    Free PMC article.
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Jan C Drooger, Bernadette A M Heemskerk-Gerritsen, +3 authors, Agnes Jager.
Breast Cancer Res Treat, 2016 Apr 12; 156(3). PMID: 27060914    Free PMC article.
The tandem duplicator phenotype as a distinct genomic configuration in cancer.
Francesca Menghi, Koichiro Inaki, +15 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2016 Apr 14; 113(17). PMID: 27071093    Free PMC article.
Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Wei Wang, Jiayi Wu, +9 authors, Li Zhu.
Oncotarget, 2016 May 05; 7(21). PMID: 27145269    Free PMC article.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
S Loibl, I Majewski, +13 authors, J Baselga.
Ann Oncol, 2016 May 15; 27(8). PMID: 27177864    Free PMC article.
Highly Cited.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.
Brett Marinelli, Carina Espinet-Col, +4 authors, Wolfgang A Weber.
Am J Nucl Med Mol Imaging, 2016 May 18; 6(2). PMID: 27186439    Free PMC article.
Approach to the Triple Negative Breast Cancer in New Drugs Area.
Mehrzad Mirzania.
Int J Hematol Oncol Stem Cell Res, 2016 Jun 03; 10(2). PMID: 27252813    Free PMC article.
Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem.
Breast Cancer (Dove Med Press), 2016 Jun 11; 8. PMID: 27284266    Free PMC article.
Highly Cited.
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Priyanka Sharma, Sara López-Tarruella, +31 authors, Miguel Martin.
Clin Cancer Res, 2016 Jun 16; 23(3). PMID: 27301700    Free PMC article.
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group.
Carsten Denkert, Stephan Wienert, +41 authors, Roberto Salgado.
Mod Pathol, 2016 Jul 02; 29(10). PMID: 27363491
Highly Cited.
Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years.
Daniel C McFarland, Jessica Naikan, +3 authors, Amy Tiersten.
J Oncol, 2016 Jul 07; 2016. PMID: 27382369    Free PMC article.
Biology and Management of Patients With Triple-Negative Breast Cancer.
Priyanka Sharma.
Oncologist, 2016 Jul 13; 21(9). PMID: 27401886    Free PMC article.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Hope S Rugo, Olufunmilayo I Olopade, +41 authors, I-SPY 2 Investigators.
N Engl J Med, 2016 Jul 15; 375(1). PMID: 27406347    Free PMC article.
Highly Cited.
Breast metastasis from vaginal cancer.
Neeraja Chandrasekaran, Daniel Scharifker, George Varsegi, Zoyla Almeida.
BMJ Case Rep, 2016 Jul 23; 2016. PMID: 27444140    Free PMC article.
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Pin Zhang, Yi Yin, +10 authors, Binghe Xu.
Oncotarget, 2016 Jul 23; 7(37). PMID: 27447966    Free PMC article.
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
Xi Jin, Yi-Zhou Jiang, +5 authors, Gen-Hong Di.
BMC Cancer, 2016 Aug 09; 16. PMID: 27495967    Free PMC article.
Concepts and targets in triple-negative breast cancer: recent results and clinical implications.
Poornima Saha, Rita Nanda.
Ther Adv Med Oncol, 2016 Sep 02; 8(5). PMID: 27583027    Free PMC article.
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani, Carsten Denkert, +20 authors, Sibylle Loibl.
Oncotarget, 2016 Sep 10; 7(42). PMID: 27611952    Free PMC article.
Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
G Houvenaeghel, R Sabatier, +11 authors, E Lambaudie.
Br J Cancer, 2016 Oct 26; 115(9). PMID: 27685443    Free PMC article.
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Mehra Golshan, Constance T Cirrincione, +11 authors, Alliance for Clinical Trials in Oncology.
Breast Cancer Res Treat, 2016 Oct 06; 160(2). PMID: 27704226    Free PMC article.
Molecular Classification of Triple-Negative Breast Cancer.
Sung Gwe Ahn, Seung Jun Kim, Cheungyeul Kim, Joon Jeong.
J Breast Cancer, 2016 Oct 11; 19(3). PMID: 27721871    Free PMC article.
Novel therapeutic strategies for patients with triple-negative breast cancer.
Jun-Fei Zhang, Jia Liu, Yu Wang, Bin Zhang.
Onco Targets Ther, 2016 Nov 02; 9. PMID: 27799799    Free PMC article.
Neoadjuvant Treatment of Breast Cancer - Advances and Limitations.
Peter A Fasching, Paul Gaß, Alexander Hein.
Breast Care (Basel), 2016 Dec 07; 11(5). PMID: 27920622    Free PMC article.
Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials.
Li-Yang Wang, Hua Xie, +3 authors, Yi Wang.
Saudi Med J, 2017 Jan 04; 38(1). PMID: 28042625    Free PMC article.
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Yu Zong, Jiayi Wu, Kunwei Shen.
Oncotarget, 2017 Jan 07; 8(10). PMID: 28061451    Free PMC article.
Systematic Review.
Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.
Carmel Jacobs, Mark Clemons, +8 authors, John Hilton.
Support Care Cancer, 2017 Jan 28; 25(6). PMID: 28127659
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study.
Xiaosong Chen, Guolin Ye, +2 authors, Kunwei Shen.
Chin J Cancer Res, 2017 Feb 09; 28(6). PMID: 28174484    Free PMC article.
The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.
Aurelio Bartolome Castrellon, Ihor Pidhorecky, Vicente Valero, Luis Estuardo Raez.
Oncol Rev, 2017 Apr 07; 11(1). PMID: 28382189    Free PMC article.
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
Cristiana Ercolani, Anna Di Benedetto, +15 authors, Marcello Maugeri-Saccà.
Cancer Biol Ther, 2017 Apr 08; 18(5). PMID: 28387539    Free PMC article.
Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.
Limei Fan, Muyou Tian, +3 authors, Jinhua Xu.
Oncotarget, 2017 Apr 19; 8(18). PMID: 28415735    Free PMC article.
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Juan Jin, Wenwen Zhang, +2 authors, Xiaoxiang Guan.
Cancer Biol Ther, 2017 May 12; 18(6). PMID: 28494179    Free PMC article.
Biological Subtypes of Triple-Negative Breast Cancer.
Michael Hubalek, Theresa Czech, Hannes Müller.
Breast Care (Basel), 2017 Jun 15; 12(1). PMID: 28611535    Free PMC article.
Germline Mutations in Triple-Negative Breast Cancer.
Eric Hahnen, Jan Hauke, +3 authors, Rita K Schmutzler.
Breast Care (Basel), 2017 Jun 15; 12(1). PMID: 28611536    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, +25 authors, Rita K Schmutzler.
JAMA Oncol, 2017 Jul 18; 3(10). PMID: 28715532    Free PMC article.
Highly Cited.
Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Karima Oualla, Heba M El-Zawahry, +7 authors, Tamer M Fouad.
Ther Adv Med Oncol, 2017 Jul 19; 9(7). PMID: 28717401    Free PMC article.
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
Fresia Pareja, Felipe C Geyer, +3 authors, Jorge S Reis-Filho.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721389    Free PMC article.
Highly Cited. Review.
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.
Felipe C Geyer, Fresia Pareja, +4 authors, Jorge S Reis-Filho.
Am J Pathol, 2017 Jul 25; 187(10). PMID: 28736315    Free PMC article.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Sinead Toomey, Alexander J Eustace, +21 authors, Bryan T Hennessy.
Breast Cancer Res, 2017 Jul 29; 19(1). PMID: 28750640    Free PMC article.
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Michael Untch, Jens Huober, +18 authors, Cornelia Liedtke.
Geburtshilfe Frauenheilkd, 2017 Aug 05; 77(6). PMID: 28769126    Free PMC article.
Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.
Marzia A Locatelli, Giuseppe Curigliano, Alexandru Eniu.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785182    Free PMC article.
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Tesa M Severson, Denise M Wolf, +16 authors, Laura van 't Veer.
Breast Cancer Res, 2017 Aug 31; 19(1). PMID: 28851423    Free PMC article.
A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy.
Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, Taizo Hirata.
Int J Surg Case Rep, 2017 Sep 11; 39. PMID: 28888915    Free PMC article.
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.
Audrey Monneur, Anthony Goncalves, +11 authors, François Bertucci.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029489    Free PMC article.
Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Fangyuan Shao, Heng Sun, Chu-Xia Deng.
Oncotarget, 2017 Oct 27; 8(42). PMID: 29069872    Free PMC article.
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
Marcus Vetter, Spyridon Fokas, +6 authors, Rosanna Zanetti-Dällenbach.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088896    Free PMC article.
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Katharina Gohr, Alexandra Hamacher, Laura H Engelke, Matthias U Kassack.
BMC Cancer, 2017 Nov 05; 17(1). PMID: 29100507    Free PMC article.
Role of Platinum in Early-Stage Triple-Negative Breast Cancer.
Alyssa La Belle, Jude Khatib, William P Schiemann, Shaveta Vinayak.
Curr Treat Options Oncol, 2017 Nov 08; 18(11). PMID: 29110096
Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Qiuhong Tian, Peng Du, +3 authors, Jinsheng Zeng.
Medicine (Baltimore), 2017 Nov 16; 96(45). PMID: 29137021    Free PMC article.
Systematic Review.
Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.
Liang Huang, Qi Liu, Sheng Chen, Zhiming Shao.
Onco Targets Ther, 2017 Dec 15; 10. PMID: 29238206    Free PMC article.
ASCO 2017: highlights in breast cancer.
Rupert Bartsch, Elisabeth Bergen.
Memo, 2017 Dec 19; 10(4). PMID: 29250202    Free PMC article.
Update Breast Cancer 2017 - Implementation of Novel Therapies.
Michael P Lux, Wolfgang Janni, +18 authors, Peter A Fasching.
Geburtshilfe Frauenheilkd, 2017 Dec 23; 77(12). PMID: 29269955    Free PMC article.
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.
Berit M Pfitzner, Bianca Lederer, +18 authors, Sibylle Loibl.
Mod Pathol, 2017 Dec 23; 31(4). PMID: 29271415
The OlympiAD trial: who won the gold?
Bishal Gyawali.
Ecancermedicalscience, 2018 Jan 02; 11. PMID: 29290761    Free PMC article.
Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.
Connie Rabanal, Rossana Ruiz, Silvia Neciosup, Henry Gomez.
World J Clin Oncol, 2018 Jan 02; 8(6). PMID: 29291168    Free PMC article.
An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth.
Toshihiko Tanno, Peng Zhang, +2 authors, Pan Zheng.
Blood Adv, 2018 Jan 04; 1(15). PMID: 29296753    Free PMC article.
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Magdalena Absmaier, Rudolf Napieralski, +9 authors, Manfred Schmitt.
Int J Oncol, 2018 Jan 13; 52(3). PMID: 29328369    Free PMC article.
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
Isabel Echavarria, Sara López-Tarruella, +19 authors, Miguel Martin.
Clin Cancer Res, 2018 Jan 31; 24(8). PMID: 29378733    Free PMC article.
Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Soo-Yeon Kim, Nariya Cho, +8 authors, Woo Kyung Moon.
Eur Radiol, 2018 Jan 31; 28(7). PMID: 29380033
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.
Claudia Omarini, Giorgia Guaitoli, +4 authors, Federico Piacentini.
Cancer Manag Res, 2018 Feb 03; 10. PMID: 29391830    Free PMC article.
OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer.
Hui-Wen Chiu, Hui-Yu Lin, Ing-Jy Tseng, Yuan-Feng Lin.
Oncotarget, 2018 Feb 09; 9(1). PMID: 29416635    Free PMC article.
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).
Arlindo R Ferreira, Otto Metzger-Filho, Roberta M B Sarmento, José Bines.
Front Oncol, 2018 Feb 09; 7. PMID: 29416986    Free PMC article.
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Xiujuan Wu, Peng Tang, +6 authors, Yi Zhang.
Nat Commun, 2018 Feb 28; 9(1). PMID: 29483583    Free PMC article.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Christoph Engel, Kerstin Rhiem, +26 authors, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
BMC Cancer, 2018 Mar 09; 18(1). PMID: 29514593    Free PMC article.
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
Nicholas McAndrew, Angela DeMichele.
J Target Ther Cancer, 2018 Mar 27; 7(1). PMID: 29577076    Free PMC article.
My burning issues in the neoadjuvant treatment for breast cancer.
Elisabeth S Bergen, Rupert Bartsch.
Memo, 2018 Apr 03; 11(1). PMID: 29606978    Free PMC article.
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Priyanka Sharma.
Curr Treat Options Oncol, 2018 Apr 16; 19(5). PMID: 29656345
Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18-19 January 2018, Cairo, Egypt.
Hesham El-Ghazaly, Adel Aref, Nermeen Bahie-Eldin.
Ecancermedicalscience, 2018 Apr 18; 12. PMID: 29662533    Free PMC article.
Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Gorka Ruiz de Garibay, Francesca Mateo, +19 authors, Miguel Angel Pujana.
Dis Model Mech, 2018 Apr 19; 11(5). PMID: 29666142    Free PMC article.
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
Naoto T Ueno, Jose Rodrigo Espinosa Fernandez, +19 authors, Wendy A Woodward.
J Cancer, 2018 May 04; 9(8). PMID: 29721054    Free PMC article.
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer.
G S Bhattacharyya, M Walia, +6 authors, P M Parikh.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721485    Free PMC article.
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim.
ESMO Open, 2018 May 17; 3(Suppl 1). PMID: 29765774    Free PMC article.
BRCA1/2 testing: therapeutic implications for breast cancer management.
Nadine M Tung, Judy E Garber.
Br J Cancer, 2018 Jun 06; 119(2). PMID: 29867226    Free PMC article.
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
Naoko Matsuda, Xiaoping Wang, +23 authors, Naoto T Ueno.
JAMA Oncol, 2018 Jun 08; 4(9). PMID: 29879283    Free PMC article.
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Angela Santonja, Alfonso Sánchez-Muñoz, +18 authors, Emilio Alba.
Oncotarget, 2018 Jun 15; 9(41). PMID: 29899867    Free PMC article.
Advances in the systemic treatment of triple-negative breast cancer.
J M Lebert, R Lester, +2 authors, J McCarthy.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910657    Free PMC article.
Highly Cited. Review.
Should age impact breast cancer management in young women? Fine tuning of treatment guidelines.
Matteo B Suter, Olivia Pagani.
Ther Adv Med Oncol, 2018 Jul 07; 10. PMID: 29977348    Free PMC article.
Therapeutic landscape in mutational triple negative breast cancer.
Yaqin Shi, Juan Jin, Wenfei Ji, Xiaoxiang Guan.
Mol Cancer, 2018 Jul 17; 17(1). PMID: 30007403    Free PMC article.
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Priyanka Sharma, Sara López-Tarruella, +30 authors, Miguel Martín.
Clin Cancer Res, 2018 Aug 01; 24(23). PMID: 30061361    Free PMC article.
Patterns and mechanisms of structural variations in human cancer.
Kijong Yi, Young Seok Ju.
Exp Mol Med, 2018 Aug 10; 50(8). PMID: 30089796    Free PMC article.
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Anna Diana, Elisena Franzese, +8 authors, Michele Orditura.
Curr Oncol Rep, 2018 Aug 22; 20(10). PMID: 30128845
Systematic Review.
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
Joerg Heil, Peter Sinn, +15 authors, Michael Golatta.
BMC Cancer, 2018 Aug 27; 18(1). PMID: 30144818    Free PMC article.
A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status.
Ying-Wen Su, Chia-Yen Hung, +2 authors, Po-Sheng Yang.
Clin Med Insights Oncol, 2018 Aug 29; 12. PMID: 30150877    Free PMC article.
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.
Alma D Campos-Parra, Eduardo López-Urrutia, +5 authors, Carlos Pérez-Plasencia.
Int J Mol Sci, 2018 Sep 14; 19(9). PMID: 30208633    Free PMC article.
Current concepts and future directions in neoadjuvant chemotherapy of breast cancer.
Rupert Bartsch, Elisabeth Bergen, Arik Galid.
Memo, 2018 Sep 18; 11(3). PMID: 30220926    Free PMC article.
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.
Ines Stevic, Volkmar Müller, +13 authors, Heidi Schwarzenbach.
BMC Med, 2018 Oct 12; 16(1). PMID: 30301470    Free PMC article.
Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer.
Cristina Pernaut, Flora Lopez, Eva Ciruelos.
Breast Care (Basel), 2018 Oct 16; 13(4). PMID: 30319326    Free PMC article.
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Paul Gass, Michael P Lux, +12 authors, Marius Wunderle.
BMC Cancer, 2018 Oct 31; 18(1). PMID: 30373556    Free PMC article.
Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy.
Kennya Medeiros L de B Lima, Allan A Lima Pereira, +4 authors, Gustavo Nader Marta.
Rep Pract Oncol Radiother, 2018 Dec 12; 24(1). PMID: 30532659    Free PMC article.
Functional profiling of nucleotide Excision repair in breast cancer.
Anne S Rajkumar-Calkins, Raphael Szalat, +11 authors, Kent W Mouw.
DNA Repair (Amst), 2019 Sep 10; 82. PMID: 31499327    Free PMC article.
Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
Florian Schütz, Peter A Fasching, +16 authors, Volkmar Müller.
Geburtshilfe Frauenheilkd, 2019 Oct 28; 79(10). PMID: 31656318    Free PMC article.
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Jessa Gilda P Pandy, Joanmarie C Balolong-Garcia, Mel Valerie B Cruz-Ordinario, Frances Victoria F Que.
BMC Cancer, 2019 Nov 11; 19(1). PMID: 31703646    Free PMC article.
Systematic Review.
Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort.
Sandra Esperanza Díaz-Casas, Jorge Alberto Castilla-Tarra, +10 authors, Juan Carlos Vergel-Martinez.
Oncologist, 2019 Jul 28; 24(12). PMID: 31346133    Free PMC article.
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
Mehra Golshan, Sibylle Loibl, +12 authors, Michael Untch.
JAMA Surg, 2020 Jan 09; 155(3). PMID: 31913413    Free PMC article.
Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
Battseren Bayarmaa, Ziping Wu, +6 authors, Liheng Zhou.
BMC Cancer, 2019 Sep 07; 19(1). PMID: 31488093    Free PMC article.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, +35 authors, Judith M Bliss.
Nat Med, 2018 May 02; 24(5). PMID: 29713086    Free PMC article.
Highly Cited.
Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer.
Chuqian Lei, Ciqiu Yang, +11 authors, Kun Wang.
J Breast Cancer, 2020 Mar 07; 23(1). PMID: 32140269    Free PMC article.
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.
Jelmar Quist, Hasan Mirza, +5 authors, Anita Grigoriadis.
Mol Cancer Ther, 2018 Oct 12; 18(1). PMID: 30305342    Free PMC article.
Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.
Sisi Wang, Tiffany M Scharadin, +5 authors, Paul T Henderson.
Chem Res Toxicol, 2018 Nov 02; 31(12). PMID: 30381944    Free PMC article.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Joaquín Gavilá, Mafalda Oliveira, +18 authors, Aleix Prat.
BMC Med, 2019 Jan 10; 17(1). PMID: 30621698    Free PMC article.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Ana C Garrido-Castro, Nancy U Lin, Kornelia Polyak.
Cancer Discov, 2019 Jan 27; 9(2). PMID: 30679171    Free PMC article.
Highly Cited. Review.
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Elena Laakmann, Isabell Witzel, +19 authors, Sibylle Loibl.
Breast Cancer Res, 2019 May 12; 21(1). PMID: 31077239    Free PMC article.
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Natalie W Harper, Kurt B Hodges, +4 authors, Edward H Romond.
Clin Breast Cancer, 2019 Jun 19; 19(4). PMID: 31208874    Free PMC article.
Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis.
Yunhai Li, Dejuan Yang, +4 authors, Guosheng Ren.
Aging (Albany NY), 2019 Aug 26; 11(16). PMID: 31446432    Free PMC article.
Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Meizhuo Gao, Tie Wang, +3 authors, Hongjiang Song.
Front Immunol, 2020 Mar 21; 11. PMID: 32194569    Free PMC article.
The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform.
Yanhui Liu, Bo Yang, +2 authors, Hailiang Liu.
Pathol Oncol Res, 2018 Nov 18; 26(1). PMID: 30443844
Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620.
Michael Untch, Sibylle Loibl, Peter A Fasching.
Breast Care (Basel), 2020 Apr 02; 15(1). PMID: 32231504    Free PMC article.
17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
Yu Zuo, Heng Xu, +6 authors, Hao Zhang.
Oncol Rep, 2020 Apr 03; 43(6). PMID: 32236631    Free PMC article.
Triple-negative breast cancer: recent treatment advances.
Alice R T Bergin, Sherene Loi.
F1000Res, 2019 Aug 27; 8. PMID: 31448088    Free PMC article.
Molecular subtypes and precision treatment of triple-negative breast cancer.
Shen Zhao, Wen-Jia Zuo, Zhi-Ming Shao, Yi-Zhou Jiang.
Ann Transl Med, 2020 May 13; 8(7). PMID: 32395543    Free PMC article.
The Landscape of Targeted Therapies in TNBC.
Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli.
Cancers (Basel), 2020 Apr 12; 12(4). PMID: 32276534    Free PMC article.
Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers.
Jieqiang Zhu, Levan Muskhelishvili, +2 authors, Minjun Chen.
Sci Rep, 2020 May 20; 10(1). PMID: 32424219    Free PMC article.
Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu.
Breast Cancer Res, 2020 Jun 11; 22(1). PMID: 32517735    Free PMC article.
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Laura M Spring, Geoffrey Fell, +10 authors, Aditya Bardia.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046998    Free PMC article.
HRness in Breast and Ovarian Cancers.
Elizabeth Santana Dos Santos, François Lallemand, +2 authors, Etienne Rouleau.
Int J Mol Sci, 2020 Jun 03; 21(11). PMID: 32481735    Free PMC article.
High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Wei Liu, Xifeng Xiong, +4 authors, Zhi Zhang.
Int J Oncol, 2020 Jul 07; 57(2). PMID: 32626933    Free PMC article.
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
Benjamin D Smith, Matthew P Goetz, Judy C Boughey.
J Clin Oncol, 2020 May 23; 38(20). PMID: 32442073    Free PMC article.
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
Jin Sun Lee, Susan E Yost, Yuan Yuan.
Cancers (Basel), 2020 Jun 04; 12(6). PMID: 32486021    Free PMC article.
Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β.
Vanessa Bellat, Alice Verchère, Sally A Ashe, Benedict Law.
BMC Cancer, 2020 Jul 18; 20(1). PMID: 32678032    Free PMC article.
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
Stefania Cocco, Michela Piezzo, +7 authors, Michelino De Laurentiis.
Int J Mol Sci, 2020 Jul 02; 21(13). PMID: 32605126    Free PMC article.
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Sanxing Guo, Sibylle Loibl, +3 authors, Carsten Denkert.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019278    Free PMC article.
Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer.
De-Di Kong, Rong-Zhan Fu, +2 authors, Shi-Bing Wang.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724406    Free PMC article.
Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
Hemant Malhotra, Pradnya Kowtal, +16 authors, Amit Verma.
JCO Glob Oncol, 2020 Jul 07; 6. PMID: 32628584    Free PMC article.
Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Ann-Kathrin Bittner, Corinna Keup, +3 authors, Sabine Kasimir-Bauer.
J Cell Mol Med, 2020 Jun 20; 24(15). PMID: 32558176    Free PMC article.
Tackling the Biological Diversity in Early Triple-Negative Breast Cancer.
Mafalda Oliveira, Cristina Saura.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774213    Free PMC article.
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
Jenny Furlanetto, Sibylle Loibl.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774215    Free PMC article.
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Robert Wesolowski, Daniel G Stover, +25 authors, Bhuvaneswari Ramaswamy.
Oncologist, 2020 May 27; 25(8). PMID: 32452601    Free PMC article.
MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
Stephen F Sener, Rachel E Sargent, +7 authors, Julie E Lang.
J Surg Oncol, 2019 Aug 11; 120(6). PMID: 31400007    Free PMC article.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Sherry X Yang, Eric Polley, Stanley Lipkowitz.
Cancer Treat Rev, 2016 Mar 21; 45. PMID: 26995633    Free PMC article.
Highly Cited. Review.
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Ke-Da Yu, Fu-Gui Ye, +19 authors, Zhi-Ming Shao.
JAMA Oncol, 2020 Aug 14; 6(9). PMID: 32789480    Free PMC article.
Early stage triple negative breast cancer: Management and future directions.
Lubna N Chaudhary.
Semin Oncol, 2020 Jun 09; 47(4). PMID: 32507668    Free PMC article.
Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.
Nikolaos Garmpis, Christos Damaskos, +14 authors, Afroditi Nonni.
In Vivo, 2020 Jul 02; 34(4). PMID: 32606140    Free PMC article.
An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Xiaotong Zhang, Gengyi Zou, +8 authors, Yi Shi.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944400    Free PMC article.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study.
Ben-Jie Shan, Xia-Bo Shen, +8 authors, Yue-Yin Pan.
Gland Surg, 2020 Sep 22; 9(4). PMID: 32953611    Free PMC article.
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer.
Qing Li, Jiani Wang, +9 authors, Binghe Xu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963461    Free PMC article.
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
Carlo Messina, Carlo Cattrini, +6 authors, Elisa Zanardi.
J Oncol, 2020 Sep 24; 2020. PMID: 32963528    Free PMC article.
Circulating microRNAs and their role in the immune response in triple-negative breast cancer.
Patricia Piña-Sánchez, Hilda-Alicia Valdez-Salazar, Martha-Eugenia Ruiz-Tachiquín.
Oncol Lett, 2020 Sep 25; 20(5). PMID: 32968446    Free PMC article.
Primary medical therapy and breast conservation treatment: the medical oncology perspective.
Nan Soon Wong.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687629    Free PMC article.
Triple-negative breast cancer: the reality in Chile and in Latin America.
Christian Caglevic, Jaime Anabalón, +6 authors, Mauricio Mahave.
Ecancermedicalscience, 2019 Feb 23; 13. PMID: 30792810    Free PMC article.
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.
Zeina Nahleh, Gehan Botrus, +3 authors, Arafat Tfayli.
Mol Clin Oncol, 2019 Mar 09; 10(3). PMID: 30847174    Free PMC article.
BRCA2 and Other DDR Genes in Prostate Cancer.
Paz Nombela, Rebeca Lozano, +3 authors, Elena Castro.
Cancers (Basel), 2019 Mar 16; 11(3). PMID: 30871108    Free PMC article.
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
Olga Caramelo, Cristina Silva, +2 authors, Teresa Almeida-Santos.
Hered Cancer Clin Pract, 2019 Apr 10; 17. PMID: 30962858    Free PMC article.
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM).
Maria Vittoria Dieci, Lucia Del Mastro, +14 authors, Stefania Gori.
Cancers (Basel), 2019 Aug 11; 11(8). PMID: 31398896    Free PMC article.
Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women.
Sandra Diaz Casas, Eder Lancheros García, +7 authors, Juan C Vergel.
Cureus, 2019 Aug 28; 11(6). PMID: 31453035    Free PMC article.
Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
Sabine Kasimir-Bauer, Corinna Keup, +3 authors, Ann-Kathrin Bittner.
Front Oncol, 2020 Oct 06; 10. PMID: 33014830    Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967    Free PMC article.
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials.
Daniele Marinelli, Marco Mazzotta, +14 authors, Patrizia Vici.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899209    Free PMC article.
Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
Athanasios Pouptsis, Leyla Swafe, Maneesha Patwardhan, Chara Stavraka.
Front Oncol, 2020 Nov 17; 10. PMID: 33194613    Free PMC article.
APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.
Kayla L Conner, Asra N Shaik, +12 authors, Steve M Patrick.
NAR Cancer, 2020 Nov 17; 2(4). PMID: 33196045    Free PMC article.
Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer.
Rajat Bajaj, Rupal Tripathi, +5 authors, Dinesh Chandra Doval.
PLoS One, 2020 Nov 12; 15(11). PMID: 33175907    Free PMC article.
Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype.
Andrea Angius, Paolo Cossu-Rocca, +7 authors, Maria Rosaria De Miglio.
Cancers (Basel), 2020 Nov 12; 12(11). PMID: 33171872    Free PMC article.
Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
Ernesto Rojas-Jiménez, Javier César Mejía-Gómez, +18 authors, Felipe Vaca-Paniagua.
Genes (Basel), 2020 Nov 25; 11(11). PMID: 33227964    Free PMC article.
Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Elaine M Walsh, Aliaa Shalaby, +6 authors, Grace M Callagy.
Breast Cancer Res Treat, 2018 Nov 30; 174(1). PMID: 30488345    Free PMC article.
Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.
Andreas D Hartkopf, Volkmar Müller, +14 authors, Hans Tesch.
Geburtshilfe Frauenheilkd, 2019 Mar 19; 79(3). PMID: 30880824    Free PMC article.
Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Andreas Schneeweiss, Carsten Denkert, +5 authors, Hans-Joachim Lück.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217629    Free PMC article.
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
Mattia Garutti, Giacomo Pelizzari, +4 authors, Fabio Puglisi.
Int J Mol Sci, 2019 Jul 13; 20(14). PMID: 31295913    Free PMC article.
Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.
Chang-Jun Wang, Ying Xu, +8 authors, Cheng-Gang Li.
Front Oncol, 2020 Dec 12; 10. PMID: 33304851    Free PMC article.
Systematic Review.
Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems.
Max S Mano.
Breast, 2020 Dec 07; 54. PMID: 33279792    Free PMC article.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Kazuko Sakai, Masahiro Tsuboi, +25 authors, Kazuto Nishio.
Cancer Sci, 2020 Nov 14; 112(1). PMID: 33185928    Free PMC article.
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.
Mariko Asaoka, Shipra Gandhi, Takashi Ishikawa, Kazuaki Takabe.
Breast Cancer (Auckl), 2021 Jan 07; 14. PMID: 33402827    Free PMC article.
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Dena Firouzabadi, Amirreza Dehghanian, +2 authors, Abdolrasoul Talei.
BMC Cancer, 2021 Jan 13; 21(1). PMID: 33430808    Free PMC article.
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Rebeca Lozano, Elena Castro, +4 authors, David Olmos.
Br J Cancer, 2020 Oct 28; 124(3). PMID: 33106584    Free PMC article.
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Stijn Moens, Peihua Zhao, +9 authors, Frédéric Amant.
Sci Rep, 2021 Feb 06; 11(1). PMID: 33542435    Free PMC article.
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Dechuang Jiao, Jingyang Zhang, +4 authors, Zhenzhen Liu.
BMC Cancer, 2021 Feb 08; 21(1). PMID: 33549037    Free PMC article.
Progress in systemic therapy for triple-negative breast cancer.
Hongnan Mo, Binghe Xu.
Front Med, 2020 Aug 14; 15(1). PMID: 32789731
Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study.
Zhiying Shao, Shalini Chaudhri, +2 authors, Daniel Rea.
Oncol Res, 2016 May 01; 23(6). PMID: 27131315    Free PMC article.
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Priyanka Sharma, Bruce F Kimler, +35 authors, Qamar Khan.
Clin Cancer Res, 2020 Nov 20; 27(4). PMID: 33208340    Free PMC article.
Update on systemic treatment in early triple negative breast cancer.
Martín Núñez Abad, Silvia Calabuig-Fariñas, +6 authors, Carlos Camps Herrero.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613695    Free PMC article.
BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update.
Noor N Junejo, Sultan S AlKhateeb.
Saudi Med J, 2020 Jan 10; 41(1). PMID: 31915789    Free PMC article.
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Yuan, Jin Sun Lee, +19 authors, Joanne Mortimer.
Oncologist, 2020 Oct 25; 26(3). PMID: 33098195    Free PMC article.
A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
Liang Huang, Guan-Tian Lang, +3 authors, A-Yong Cao.
Ann Transl Med, 2021 Mar 13; 9(4). PMID: 33708928    Free PMC article.
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sagar Sardesai, Mohamed Badawi, +17 authors, Robert Wesolowski.
Invest New Drugs, 2020 Jan 19; 38(5). PMID: 31953695    Free PMC article.
Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data.
Benjamín Walbaum, Francisco Acevedo, +15 authors, César Sánchez.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777171    Free PMC article.
Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital.
Francisco Acevedo, Militza Petric, +14 authors, Raúl Martinez.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777178    Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, +10 authors, Alexandr Poprach.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33808149    Free PMC article.
Update on systemic treatment for newly diagnosed inflammatory breast cancer.
Sudpreeda Chainitikun, Sadia Saleem, +2 authors, Naoto T Ueno.
J Adv Res, 2021 Apr 13; 29. PMID: 33842000    Free PMC article.
A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
Rongrong Wu, Kayo Adachi, +11 authors, Takashi Ishikawa.
J Surg Case Rep, 2021 Apr 23; 2021(4). PMID: 33884162    Free PMC article.